Phathom Pharmaceuticals, Inc. (PHAT) key performance indicators and operating metrics (10 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Research and Development Expenses | 7.8M | FY2026-Q1 |
| Operating Expenses (GAAP) | 61.8M | FY2026-Q1 |
| Adjusted Net Loss Per Share (Basic and Diluted) (Non-GAAP) | -0.18 USD_per_share | FY2026-Q1 |
| Selling General and Administrative Expenses | 54M | FY2026-Q1 |
| Total Non-GAAP Operating Expenses | 56.2M | FY2026-Q1 |
| Total VOQUEZNA Prescriptions Filled (to Date) | 1.35M | FY2026-Q1 |
| Adjusted Net Loss (Non-GAAP) | 5.7M | FY2025-Q4 |
| Filled Prescriptions in the Quarter (VOQUEZNA) | 221K | FY2025-Q3 |
| Selling General and Administrative Expense | 51.6M | FY2025-Q3 |
| Cumulative Voquezna Prescribers | 20K | FY2024-Q4 |
Back to PHAT overview · PHAT earnings · PHAT holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.